PPARG and prostate carcinoma: To investigate the mechanisms of the PPARγ agonist-induced prostate cancer cell growth inhibition, the authors examined the effect of troglitazone on the expression of PPARγ and GSK-3β, activity of NFκB, as well as on the prostate cancer cell growth.